News – BioTuesdays

Developments

Azura Ophthalmics posts positive Phase 2 results in Meibomian gland dysfunction

Closely-held Azura Ophthalmics of Israel announced positive topline results from a Phase 2 program evaluating the company’s investigational therapy for the treatment of Meibomian gland dysfunction (MGD). The company’s...

March 5, 2021

Markets

Echelon starts Diagnos at speculative buy; PT 85 cents (Canadian)

Echelon Capital Markets initiated coverage of Diagnos (TSXV:ADK) with a “speculative buy” rating and price target of 85 cents (Canadian). The stock closed at 60 cents on March 4. ADK is a commercial-stage artificial...

March 5, 2021

Markets

Canaccord ups TransMedics PT to $46 from $20

Canaccord Genuity raised its price target for TransMedics (NASDAQ:TMDX) to $46 from $20, predicting 2021 would be transformational with two potential product approvals and a roll-out of an enhanced support model. The...

March 3, 2021

Markets

Maxim starts NLS Pharmaceutics at buy; PT $8

Maxim Group launched coverage of NLS Pharmaceutics AG (NASDAQ:NLSP) with a “buy” rating and $8 price target. The stock closed at $2.83 on March 2. NLS is developing Quilience for narcolepsy and Nolazol for ADHD; both...

March 3, 2021

Executive Moves

Medtech analyst Raj Denhoy joins Establishment Labs as head of strategy, IR

Establishment Labs Holdings (NASDAQ: ESTA) appointed Raj Denhoy as head of strategy and investor relations to help define and execute the company’s corporate strategy and communicate that vision to investors and other...

March 3, 2021

Executive Moves

Profound Medical appoints healthcare investment professional Cynthia Lavoie to board

Profound Medical (NASDAQ:PROF; TSX:PRN) appointed seasoned healthcare investment professional Cynthia Lavoie, Ph.D., to the board of the commercial-stage medical device company that develops and markets customizable...

March 3, 2021

Markets

Cantor starts Heat Biologics at OW; PT $22

Cantor Fitzgerald initiated coverage of Heat Biologics (NASDAQ:HTBX) with an “overweight” rating and $22 price target. The stock closed at $7.87 on March 2. Heat Biologics is developing proprietary immunotherapy...

March 3, 2021

Markets

Analysts start Bolt Biotherapeutics at OP, buy; PTs $36 and $40

Analysts for SVB Leerink and Stifel launched coverage of Bolt Biotherapeutics (NASDAQ:BOLT) with “outperform” and “buy” ratings, respectively, and price targets of $36 and $40, respectively. The stock closed at $30 on...

March 2, 2021

Markets

Stifel starts Angion Biomedica at buy; PT $40

Stifel launched coverage of Angion Biomedica (NASDAQ:ANGN) with a “buy” rating and $40 price target. The stock closed at $19.92 on March 1. Angion’s lead asset, ANG-3777, is a mimetic of hepatocyte growth factor (HGF)...

March 2, 2021

Markets

SVB Leerink starts Pharvaris at OP; PT $50

SVB Leerink initiated coverage of Pharvaris B.V. (NASDAQ:PHVS) with an “outperform” rating and $50 price target. The stock closed at $39.23 on March 1. Pharvaris is developing therapies for rare diseases, with a focus...

March 2, 2021

Markets

Piper starts Avita Medical at OW; PT $27

Piper Sandler launched coverage of Avita Medical (NASDAQ:RCEL) with an “overweight” rating and $27 price target. The stock closed at $21.49 on March 1. Avita makes Recell, which uses a patient’s own skin to make a cell...

March 2, 2021

Markets

WB starts Lucira Health at OP

William Blair initiated coverage of Lucira Health (NASDAQ:LHDX) with an “outperform” rating, based on “our outlook for a series of positive catalysts on commercialization and manufacturing as well as what we believe is...

March 2, 2021

Azura Ophthalmics posts positive Phase 2 results in Meibomian gland dysfunction

Echelon starts Diagnos at speculative buy; PT 85 cents (Canadian)

Canaccord ups TransMedics PT to $46 from $20

Maxim starts NLS Pharmaceutics at buy; PT $8

Medtech analyst Raj Denhoy joins Establishment Labs as head of strategy, IR

Profound Medical appoints healthcare investment professional Cynthia Lavoie to board

Cantor starts Heat Biologics at OW; PT $22

Analysts start Bolt Biotherapeutics at OP, buy; PTs $36 and $40

Stifel starts Angion Biomedica at buy; PT $40

SVB Leerink starts Pharvaris at OP; PT $50

Piper starts Avita Medical at OW; PT $27

WB starts Lucira Health at OP

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter